Get the Stockscreener App
4.96
1.02%
0.05
After Hours:
4.96
Taysha Gene Therapies Inc stock is traded at $4.96, with a volume of 2.68M.
It is up +1.02% in the last 24 hours and up +51.68% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$4.91
Open:
$4.91
24h Volume:
2.68M
Relative Volume:
0.45
Market Cap:
$1.35B
Revenue:
$8.10M
Net Income/Loss:
$-92.72M
P/E Ratio:
-13.89
EPS:
-0.3571
Net Cash Flow:
$-82.52M
1W Performance:
+4.42%
1M Performance:
+51.68%
6M Performance:
+155.67%
1Y Performance:
+193.49%
1-Day Range:
$4.85
$5.20
1-Week Range:
$4.695
$5.25
52-Week Range:
$1.05
$5.5082
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.96 | 1.34B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Will breakout in Taysha Gene Therapies Inc. lead to full recoveryJuly 2025 Market Mood & Weekly High Potential Stock Alerts - newser.com
Short interest data insights for Taysha Gene Therapies Inc.Bear Alert & Low Drawdown Momentum Ideas - newser.com
Will a bounce in Taysha Gene Therapies Inc. offer an exitJuly 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Can momentum traders help lift Taysha Gene Therapies Inc.Weekly Investment Report & Fast Momentum Entry Tips - newser.com
Why Taysha Gene Therapies Inc. stock is favored by top institutionsWeekly Trend Report & Low Risk High Win Rate Stock Picks - newser.com
How institutional ownership impacts Taysha Gene Therapies Inc. stockJuly 2025 Review & Capital Efficiency Focused Strategies - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies (TSHA) Expected to Announce Earnings on Tuesday - MarketBeat
Candlestick signals on Taysha Gene Therapies Inc. stock todayJuly 2025 Opening Moves & Weekly Momentum Stock Picks - newser.com
Why Taysha Gene Therapies Inc. stock is rated strong buy2025 Top Decliners & Verified Swing Trading Watchlist - newser.com
Taysha Gene Therapies’ REVEAL Adult Study: A New Hope for Rett Syndrome? - TipRanks
Published on: 2025-10-29 21:17:59 - newser.com
Can Taysha Gene Therapies Inc. stock beat market expectations this quarterPortfolio Gains Summary & Risk Controlled Swing Alerts - fcp.pa.gov.br
Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Market Sentiment & Stock Timing and Entry Methods - fcp.pa.gov.br
Will Taysha Gene Therapies Inc. stock maintain momentum in 2025 - Fundação Cultural do Pará
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 - The Manila Times
Taysha Gene Therapies (NASDAQ: TSHA) sets Nov. 4, 8:30 a.m. ET call and webcast - Stock Titan
What catalysts could drive Taysha Gene Therapies Inc. stock higherJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - fcp.pa.gov.br
Aug Levels: What catalysts could drive Taysha Gene Therapies Inc. stock higherRecession Risk & Free Safe Entry Trade Signal Reports - fcp.pa.gov.br
Can Taysha Gene Therapies Inc. stock sustain institutional interest2025 Retail Activity & Low Risk High Win Rate Stock Picks - fcp.pa.gov.br
Tybourne Capital Management HK Ltd. Grows Stock Position in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Published on: 2025-10-27 02:39:07 - newser.com
Published on: 2025-10-27 01:34:16 - newser.com
Published on: 2025-10-26 23:07:10 - newser.com
Published on: 2025-10-26 19:19:29 - newser.com
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):